Section 01
What NAD+ Actually Is
⚠️Category Clarification: NAD+ Is Not a Peptide
NAD+ (Nicotinamide Adenine Dinucleotide) is a dinucleotide coenzyme, not a peptide. Peptides are short chains of amino acids. NAD+ shares no structural lineage with peptides. Wellness clinics that market "peptide and NAD+ infusions" in the same breath are conflating two distinct pharmacological categories with different mechanisms, evidence bases, and regulatory pathways. VitalRx treats NAD+ as its own category for exactly this reason.
NAD+ is a molecule found in every living cell. It is involved in over 500 enzymatic reactions, functioning primarily as an electron carrier in metabolic pathways (the NAD+/NADH redox couple) and as a substrate consumed by longevity-associated proteins called sirtuins (SIRT1-7) and DNA repair enzymes called PARPs. Without sufficient NAD+, these pathways slow down. Cells produce less energy. DNA repair becomes less efficient. The hallmarks of biological aging accelerate.
The reason NAD+ has attracted intense commercial interest is that it declines measurably with age. Studies estimate a decline of roughly 50% in NAD+ levels between ages 40 and 60 in multiple tissues. This decline correlates with many age-associated changes in physiology. Whether reversing that decline through supplementation produces clinically meaningful benefits in humans is the central unresolved question in the field.
500+
Enzymatic reactions requiring NAD+ as a cofactor
~50%
Estimated NAD+ decline between ages 40 and 60 in key tissues
2025
Year Nature Metabolism documented the gap between preclinical promise and human outcomes
The distinction between raising blood NAD+ levels and achieving meaningful intracellular effects is the fault line in the entire category. Multiple trials confirm that oral NMN and NR raise blood NAD+ measurably. The harder question, which most supplement marketing skips, is whether that bloodstream elevation translates into cellular and tissue-level changes that a person would actually notice or that extend healthspan.
Section 02
Who It's Actually For
The honest answer is that NAD+ supplementation has the strongest rationale for older adults with documented NAD+ decline and people with specific clinical conditions. The weakest rationale is for healthy adults under 40 who have not measured their NAD+ baseline and are chasing vague performance improvements.
| Profile | Rationale | Evidence Strength | Fit |
|---|---|---|---|
Adults 50+ with documented NAD+ decline Baseline blood NAD+ below reference range | Documented decline provides direct clinical rationale for repletion. This is the population animal studies most closely model. | Moderate (RCTs confirm NAD+ elevation; functional outcomes variable) | Best Fit |
Individuals with metabolic dysfunction Pre-diabetes, elevated inflammation markers | NAD+ plays a role in insulin signaling and glucose metabolism. Some RCTs show modest improvements in metabolic markers. | Modest human data; more robust in animal models | Good Fit |
Biohacker optimizers with testing infrastructure Will baseline, track, and adjust | If you measure your NAD+ before, during, and after, you can actually determine whether supplementation is changing your biology. | Individual N=1 data possible; subjective outcomes unreliable without measurement | Good Fit |
Addiction recovery support Alongside licensed addiction treatment, not as standalone | NAD+ depletion occurs in chronic substance use. Pilot data (one study, 70% cravings relief) is preliminary. No large-scale RCT exists. | Weak human evidence; biologically plausible mechanism | Conditional Fit |
Healthy adults under 40 seeking 'optimization' No baseline testing, no documented decline | NAD+ levels in healthy young adults are generally adequate. Benefits in this population are not supported by clinical evidence. | No meaningful human RCT evidence for this population | Poor Fit |
Profile
Baseline blood NAD+ below reference range
Rationale
Evidence Strength
Fit
Profile
Pre-diabetes, elevated inflammation markers
Rationale
Evidence Strength
Fit
Profile
Will baseline, track, and adjust
Rationale
Evidence Strength
Fit
Profile
Alongside licensed addiction treatment, not as standalone
Rationale
Evidence Strength
Fit
Profile
No baseline testing, no documented decline
Rationale
Evidence Strength
Fit
🔬The Undersold Neuroprotection Signal
One secondary area of genuine scientific interest that wellness marketing tends to underemphasize in favor of "anti-aging" messaging: NAD+ plays a role in neuronal survival and synaptic plasticity through SIRT1 and PARP1 pathways. Several early studies suggest potential relevance to neurodegenerative conditions. This signal is preliminary but scientifically credible in a way that broad "energy and aging" claims often are not.
Section 03
How It Works
NAD+ operates through four major mechanism clusters, each with a distinct cellular role. Understanding these mechanisms is important because they explain both why the molecule matters and why delivery method has such enormous consequences for efficacy.
Redox Cycling: The Energy Shuttle
NAD+ accepts electrons from metabolic reactions (becoming NADH), and NADH donates those electrons to the mitochondrial electron transport chain to generate ATP. This is not a peripheral function. It is the central mechanism of cellular energy production. Without sufficient NAD+, mitochondria cannot run efficiently. This is the foundation of the "energy" claim, and it is mechanistically sound. The clinical question is whether supplementation at typical doses meaningfully increases the rate of this process in humans with normal baseline NAD+.
Sirtuin Activation: The Longevity Pathway
Sirtuins (SIRT1-7) are NAD+-dependent enzymes involved in gene expression regulation, DNA repair, and cellular stress responses. They consume NAD+ in the process of deacetylating target proteins. As NAD+ declines with age, sirtuin activity declines proportionally. The hypothesis that boosting NAD+ restores sirtuin function and thus delays aging is the scientific basis for the longevity narrative. In animal models, this mechanism has produced dramatic results. In human RCTs, the outcomes have been modest and inconsistent.
PARP Activation: DNA Repair
PARP enzymes consume NAD+ to initiate DNA strand break repair. DNA damage accumulates with age and with metabolic stress. In theory, maintaining NAD+ availability supports more robust DNA repair. In practice, PARP activation also competes with sirtuins for available NAD+, meaning that high DNA damage burden could deplete NAD+ faster than supplementation replenishes it.
CD38 Competition: The Aging Drain
CD38 is an enzyme whose activity increases significantly with age and inflammation. It degrades NAD+ at a rate that accelerates the age-related decline. This makes CD38 a key reason why older adults have lower NAD+ despite no change in dietary intake. Several researchers have proposed that NAD+ supplementation alone may be insufficient without also addressing CD38 overactivity, though pharmacological CD38 inhibition in humans is still experimental.
🔬Why NAD+ IV Doesn't Work the Way Clinics Claim
IV delivery achieves 100% bloodstream bioavailability. However, NAD+ cannot cross cell membranes directly at meaningful rates. To enter cells, extracellular NAD+ must be broken down by ectonucleotidases into smaller components (nicotinamide, NMN, NR) and then reconstructed intracellularly. Dr. Eric Verdin, President of the Buck Institute for Research on Aging, has stated that IV NAD+ is "mostly broken down into nicotinamide when injected," and that oral precursors are likely more effective at raising intracellular NAD+. A 2019 study found that most IV-administered NAD+ ended up in urine over a six-hour infusion period. This does not mean IV NAD+ does nothing, but it undermines the primary clinical justification for its $750-1,500 price premium.
Section 04
Realistic Expectations
The NAD+ category has the highest ratio of dramatic promise to modest clinical outcome of nearly any supplement category. The realistic timeline for supervised oral NMN or NR supplementation reflects this gap honestly.
⚠️Non-Responder Rate: Not Quantified for Anti-Aging Outcomes
The honest answer is that non-responder rates for subjective outcomes (energy, cognition, sleep) have not been rigorously quantified in human RCTs because most trials measure blood NAD+ levels rather than functional outcomes. A 2025 meta-analysis of NAD+ precursor trials found that "most clinically relevant outcomes showed no significant difference from placebo despite NAD+ elevation." Translated to consumer language: many people will see their blood NAD+ rise on supplementation and notice no change in how they feel. This is not a product defect. It is the current state of the evidence.
No Perceptible Change Expected
NAD+ precursors begin raising blood NAD+ levels, but this elevation does not produce immediate subjective effects in most users. Any energy changes reported in this window are likely attributable to the behavioral context of starting a new health protocol (placebo, improved sleep hygiene, dietary changes).
Possible Mild Shifts in Energy or Sleep Quality
Some users in clinical trials and consumer cohorts report modest improvements in perceived energy and sleep depth in this window. These improvements are inconsistent across populations and not observed in all trials. They appear more commonly in adults over 50 with documented baseline NAD+ insufficiency.
Measurable Blood NAD+ Elevation Confirmed
This is the window in which follow-up blood testing will confirm whether your NAD+ levels have risen. The 2022 Cell Metabolism RCT documented significant blood NAD+ elevation in middle-aged adults at this timepoint. Confirmation of NAD+ elevation does not guarantee functional benefit, but it does confirm the intervention is pharmacologically active.
Modest Long-Term Benefits in Specific Populations
Longer-term trials (6-12 months) in older adults and metabolically challenged populations show the most consistent positive signals: modestly improved insulin sensitivity, some cardiorespiratory metrics, and in one study, improved muscle function in older adults. These benefits are population-specific and effect sizes are modest. "Reverse aging" remains unsupported by the human data.
⚠️Reversibility: What Happens When You Stop
Blood NAD+ levels return toward baseline within approximately 2-4 weeks of discontinuing NMN or NR supplementation. There is no published evidence of a "durable" effect that persists after stopping, unlike some other interventions. This means NAD+ supplementation requires ongoing commitment to maintain whatever blood level elevation it achieves. Any benefits experienced during the protocol will likely attenuate within a month of stopping.
Section 05
Dosing Protocol
Dosing in the NAD+ category is complicated by three separate debates: which form to use (NMN vs. NR), what dose to use, and what time of day optimizes absorption. The table below reflects the current clinical evidence, the community consensus, and the VitalRx supervised approach.
| Approach | Form | Dose | Timing | Evidence Basis |
|---|---|---|---|---|
| Published RCT Range (NMN) | Oral NMN capsule | 250 mg – 2,000 mg daily | Morning, fasted preferred | Human RCT NPJ Aging 2020; Cell Metabolism 2022 |
| Published RCT Range (NR) | Oral NR capsule | 300 mg – 1,000 mg daily | Morning, with or without food | Human RCT Nature Communications; multiple trials |
| VitalRx Supervised Protocol | Physician-selected, verified NMN or NR based on baseline labs | 500 mg daily (starting); adjusted at 8-week review | Morning, fasted (2h without food). Consistency matters more than exact time. | RCT-Anchored Dose within published safety data; titration by lab results |
| Community Gray Market | Amazon NMN or NR (variable quality) | Self-selected, typically 250-500 mg | Variable; inconsistent | Quality Unverified 50%+ failed label claims (2024-25) |
| IV Infusion (Clinic Protocol) | Injectable NAD+ via IV | 500 mg - 1,000 mg per session | 2-4 hours in clinic; 1-4 sessions/month | Contested High blood bioavailability; cellular uptake disputed |
Approach
Form
Dose
Timing
Evidence Basis
Approach
Form
Dose
Timing
Evidence Basis
Approach
Form
Dose
Timing
Evidence Basis
Approach
Form
Dose
Timing
Evidence Basis
Approach
Form
Dose
Timing
Evidence Basis
The Fasting Question
Unlike GH secretagogues, where insulin suppression directly competes with the mechanism, the fasting rationale for NAD+ precursors is less mechanistically rigid. That said, absorption of NMN appears enhanced in a fasted state based on pharmacokinetic data, and morning fasted dosing is the convention used in most human RCTs. Taking NR with or without food appears to have less impact on absorption.
✦How VitalRx's Protocol Differs from Self-Dosing
Self-directed NAD+ supplementation has three failure modes: buying a product that contains negligible active ingredient (documented in over 50% of Amazon products tested), dosing based on marketing copy rather than your actual baseline, and having no way to measure whether it's working. VitalRx starts with a blood NAD+ baseline. We select a quality-verified product with a certificate of analysis from a 503B-registered supplier. We re-test at 8 weeks. If your levels haven't moved, we adjust. If they have, we discuss what that means for your protocol going forward. No other provider currently offers this cycle.
Section 06
Cycling: Evidence vs. Myth
⚠️No Evidence Base for Cycling NAD+ Precursors
The cycling protocols that dominate NAD+ community discussion (5 days on / 2 days off; 3 months on / 1 month off) have no basis in published human RCT data. They originate from precaution-based community heuristics borrowed from other supplement categories. NAD+ is a coenzyme that the body produces and consumes continuously. There is no pharmacological rationale for cycling based on receptor desensitization or downregulation. The main argument for cycling is cost management, not science.
| Cycling Claim | Community Belief | Evidence Status |
|---|---|---|
| 'Your body stops responding to continuous NAD+' | Widespread belief; drives 5/2 protocols | No Human Evidence No published RCT supports tolerance or tachyphylaxis to NAD+ precursors |
| 'Cycling gives your sirtuins a break' | Heard frequently in biohacker communities | Mechanistically Backwards Sirtuin activity is limited by NAD+ availability; restricting NAD+ reduces sirtuin activity |
| 'Monthly breaks reset sensitivity' | Extrapolated from stimulant/adaptogen protocols | No Basis Extrapolation from pharmacologically distinct compounds |
| Continuous dosing is safe long-term | Held by researchers and informed biohackers | Supported NPJ Aging 2020 showed NMN safe at 2,000 mg/day; NR has longest safety record |
Cycling Claim
Community Belief
Evidence Status
Cycling Claim
Community Belief
Evidence Status
Cycling Claim
Community Belief
Evidence Status
Cycling Claim
Community Belief
Evidence Status
VitalRx's physician-supervised protocol uses continuous supplementation consistent with published RCT design. Protocol interruptions are driven by clinical factors (significant side effects, lab-indicated adjustments, planned procedural contexts) rather than arbitrary calendar cycling. If cost is the driver, we discuss dosage reduction during re-check rather than complete cessation.
Section 07
Quality-Verified Protocol
The most predictable failure mode in the NAD+ supplement market is not a bad protocol. It is a protocol run on a product that contains no meaningful active ingredient. An independent 2024-2025 analysis of 22 top-selling Amazon NAD+ products found that approximately half contained negligible NAD+ precursor content. A separate 2021 analysis of NMN-specific products found that only 14% met their label claims.
"I bought three different NMN brands. Sent all three to a third-party testing service. One was basically filler. One had about 60% of claimed content. One was legit. You cannot tell from the bottle."
— r/NMN community, aggregated consumer research 2024-25
✦Quality-Verified. Certificate of Analysis. Physician-Selected.
VitalRx sources NMN and NR from suppliers with third-party Certificates of Analysis confirming active ingredient content. We have reviewed the testing documentation. Our physician selects the specific product for your protocol based on current testing data, not affiliate commission or brand relationship. The supplement channel cannot verify what you receive. We can.
0
Guesswork about whether your product contains what it claims
COA
Certificate of Analysis on every product we recommend or source
503B
Registered facility sourcing for injectable NAD+ protocols where applicable
What Your Protocol Includes
A VitalRx NAD+ protocol is not a bottle of capsules with a prescription slip attached. It is a structured clinical engagement: a baseline blood draw before any supplementation begins, a physician review of your labs and health context, a specific product recommendation with documented quality verification, a 30-day check-in, and an 8-week re-test to determine whether your blood NAD+ has moved and what to do based on that result.
⚡Storage and Handling Notes
NMN and NR are relatively stable at room temperature when stored away from heat and moisture. Premium NMN products should be stored below 25°C (77°F). Exposure to heat or humidity degrades the active compound. Products shipped without temperature control for extended periods in summer may lose potency before they reach the consumer. VitalRx ships with appropriate packaging; if your protocol includes any injectable formulation, cold-chain shipping applies and instructions will be included with your shipment.
Section 08
Lab Monitoring
Lab monitoring in the NAD+ context serves a purpose that no other NAD+ provider currently offers at scale: it tells you whether the intervention is actually working in your body. "I feel more energized" cannot distinguish NAD+ effects from placebo, lifestyle change, or the behavioral impact of paying attention to your health. Blood NAD+ levels can.
VitalRx requires a baseline panel before initiating any NAD+ protocol and a follow-up at 8 weeks. Additional markers are monitored because NAD+ affects metabolic pathways with relevance to glucose regulation and inflammation.
Marker 01
Whole Blood NAD+
Target: Establishes personal baseline; re-test at 8 weeks
The only way to know if your supplementation is pharmacologically active. Blood NAD+ elevation is confirmed in multiple RCTs. No elevation at 8 weeks = product quality problem or absorption issue.
Marker 02
Fasting Glucose
Target: 70-99 mg/dL
NAD+ affects insulin sensitivity and glucose metabolism. Baseline fasting glucose establishes metabolic context for the protocol.
Marker 03
HbA1c
Target: Below 5.7%
3-month glucose average provides context. For patients in the pre-diabetic range, NAD+'s potential metabolic benefits are most likely clinically meaningful.
Marker 04
Comprehensive Metabolic Panel
Reference range varies by lab
Liver function, kidney function, and electrolytes establish systemic health baseline. High-dose NMN above 1,000mg has not shown hepatotoxicity, but baseline CMP is standard.
Marker 05
hs-CRP (High-Sensitivity C-Reactive Protein)
Target: Below 1.0 mg/L (optimal); below 3.0 mg/L (acceptable)
Chronic inflammation is a driver of NAD+ depletion via CD38 overactivation. Elevated hs-CRP suggests NAD+ supplementation may be fighting an active depletion mechanism.
Marker 06
Complete Blood Count (CBC)
Reference range varies by lab
General health baseline marker. NAD+ has theoretical relevance to red blood cell function via oxidative metabolism. No known adverse CBC effects from NMN or NR.
✦Why We Require Baseline Labs Before Starting
Most NAD+ providers, supplement brands, and IV clinics do not require any bloodwork. This is a commercial convenience, not a clinical standard. Without knowing where you started, you cannot know whether the protocol is working. Without knowing your metabolic baseline, a physician cannot make an informed recommendation about dose or form. VitalRx's baseline panel is not a formality. It is the clinical foundation that makes the entire protocol meaningful rather than guesswork.
Section 09
Stacking
NAD+ precursors combine most rationally with compounds that address adjacent longevity mechanisms. The goal of a well-designed stack is not to accumulate everything that has appeared in a longevity podcast. It is to address complementary pathways with compounds that have independent evidence, without creating metabolic competition or undue cost.
| Compound | Mechanism Class | Rationale with NAD+ | VitalRx Availability |
|---|---|---|---|
| Resveratrol or Pterostilbene | SIRT1 activator / Polyphenol | Resveratrol activates SIRT1 in a manner that requires NAD+ as a cofactor. Providing both addresses two rate-limiting factors simultaneously. Pterostilbene has better bioavailability. | Available |
| CoQ10 (Ubiquinol form) | Mitochondrial electron transport cofactor | CoQ10 works downstream of NAD+ in the mitochondrial electron transport chain. Both are required for efficient ATP synthesis. | Available |
| Magnesium Glycinate | ATP cofactor / Systems support | ATP exists primarily as Mg-ATP in cells. Magnesium deficiency impairs multiple NAD+-dependent enzymatic reactions. | Available |
| Vitamin D3 + K2 | Gene expression / Immune modulation | Vitamin D3 influences longevity-relevant gene expression pathways and is widely deficient in adults over 50, the primary NAD+ target population. | Available |
| Creatine Monohydrate | Phosphocreatine / Energy buffer | Creatine and NAD+ support ATP availability through different mechanisms. Among the most well-evidenced supplements for muscle and cognition in older adults. | Available |
Compound
Mechanism Class
Rationale with NAD+
VitalRx Availability
Compound
Mechanism Class
Rationale with NAD+
VitalRx Availability
Compound
Mechanism Class
Rationale with NAD+
VitalRx Availability
Compound
Mechanism Class
Rationale with NAD+
VitalRx Availability
Compound
Mechanism Class
Rationale with NAD+
VitalRx Availability
⚠️Avoid: High-Dose Niacin Combined with NMN or NR
Niacin (nicotinic acid) is converted to NAD+ via the same salvage pathway as NMN and NR. Adding all three simultaneously creates pathway overlap without additive benefit at clinically meaningful doses, while increasing the risk of niacin-mediated flushing and potential liver stress at high doses. Use one primary precursor (NMN or NR) as your NAD+ pathway supplement.
Section 10
Pricing
⚠️The Number Most Vendors Hide
IV NAD+ clinics advertise session prices but not the total cost of a meaningful protocol (typically 3-5 sessions for initial therapy plus monthly maintenance). Supplement brands advertise bottle prices but not the probability that the product contains what it claims. Gray market oral NMN starts at $30/month but has a documented 50%+ failure rate on independent quality testing. The relevant comparison is cost-per-verified-outcome, not cost-per-capsule.
| Option | Monthly Cost | What's Included | Quality Verification |
|---|---|---|---|
| IV NAD+ Clinics | $750 - $1,500 per session; $2,800+ for 5 sessions | IV infusion in clinic. No standard labs. No follow-up NAD+ testing. Scientific rationale for cellular benefit disputed. | Clinic-Sourced Variable; no public COA standard |
| Other Medical Clinics (Oral) | From $99 advertised | Physician consult for prescription; no standardized baseline or follow-up testing documented publicly. | Unknown Product sourcing not publicly documented |
VitalRx — Month 1 Includes Baseline Lab Panel | $199 all-in | Physician consultation + baseline blood NAD+ and metabolic panel + quality-verified NMN or NR (60-day supply) + 30-day check-in + 8-week re-test scheduling | COA Verified |
| VitalRx — Month 2+ | $129/month | Ongoing quality-verified supplement supply + physician oversight + labs at 8-week follow-up (included in first cycle) | COA Verified |
| Gray Market (Amazon, direct sites) | $30 - $80/month | Product only. No physician oversight. No testing. Independent testing found ~50% contain negligible active ingredient. | Unverified |
Option
Monthly Cost
What's Included
Quality Verification
Option
Monthly Cost
What's Included
Quality Verification
Option
Includes Baseline Lab Panel
Monthly Cost
What's Included
Quality Verification
Option
Monthly Cost
What's Included
Quality Verification
Option
Monthly Cost
What's Included
Quality Verification
IV NAD+ Clinics
$750 - $1,500/session
IV infusion. No standard labs. Scientific rationale disputed.
Clinic-SourcedOther Medical Clinics
From $99
Physician consult. No standardized testing documented.
UnknownVitalRx — Month 1
$199 all-in
Physician + baseline labs + quality-verified supplement + 30-day check-in + 8-week re-test
COA VerifiedVitalRx — Month 2+
$129/month
Ongoing supplement + physician oversight + follow-up labs
COA VerifiedGray Market (Amazon)
$30-$80/month
Product only. ~50% fail independent quality testing.
UnverifiedPrice Breakdown: What You're Actually Paying For
Component
Quality-Verified NMN or NR
Included in monthly cost
COA-verified product from audited supplier. Not the Amazon lottery.
Component
Physician Consultation
Included in Month 1
Licensed physician reviews your labs and health history; determines NMN vs. NR, starting dose, and contraindications.
Component
Baseline + Follow-Up Labs
Included in Month 1; re-test at 8 weeks
Blood NAD+ baseline and 6-marker metabolic panel. The only way to know whether your protocol is pharmacologically active.
Component
Supplies and Shipping
Included
Standard shipping for oral supplementation protocols. Temperature-controlled where applicable.
✦Why Month 1 Costs More: The Baseline Rationale
Month 1 includes a blood NAD+ baseline test that costs $100-150 from commercial labs. We bundle this into the first-month cost because a protocol without a baseline is pharmacologically meaningless. You cannot determine whether NMN or NR is raising your NAD+ levels without knowing where you started. From Month 2 forward, your cost reflects ongoing quality-verified supplementation and physician oversight.
Section 11
Legal Access in All 50 States
NAD+ occupies a regulatory environment that is meaningfully different from the peptide category that VitalRx also serves. Understanding this difference matters for patients and providers.
DSHEA Supplement Pathway
Oral NMN and NR sold legally in all 50 states without prescription
503B Compounding (Injectable)
Injectable NAD+ available through licensed compounding pharmacy with prescription
Not FDA-Approved Drug
No NAD+ or precursor has FDA drug approval; physician use is off-label
WADA: Not Prohibited
NAD+ and precursors not on WADA prohibited list as of 2026
The Three-Layer Regulatory Picture
Oral NMN and NR (DSHEA supplements): These are legal to purchase and use without a prescription in all 50 states. They are classified as dietary supplements under DSHEA. The FDA issued a warning letter in 2022 suggesting NMN might be reclassified as a drug, but the FDA did not enforce this position and NMN remains commercially available as of March 2026. This regulatory ambiguity is worth monitoring but does not represent an imminent threat to access.
Injectable NAD+ (IV, subcutaneous, nasal): Compounded NAD+ for parenteral use requires a physician prescription and sourcing from a licensed 503A compounding pharmacy or 503B outsourcing facility. Unlike the peptide category, NAD+ has not been the target of the FDA enforcement actions that disrupted the peptide market in 2024-2025.
Addiction treatment context: Claims that NAD+ "treats," "cures," or produces specific clinical outcomes in addiction contexts may require FDA clearance. VitalRx positions NAD+ as potentially supportive within a broader treatment context, not as a standalone addiction treatment.
✦How VitalRx Navigates the Oral and Injectable Pathways
For most patients, VitalRx's NAD+ protocol uses physician-supervised, quality-verified oral NMN or NR. This is the clinically appropriate primary pathway given the contested evidence for IV bioavailability. Where a patient specifically requests IV NAD+ or presents a clinical context appropriate for parenteral delivery, VitalRx sources through 503A-compliant compounding pharmacy channels.
⚡RFK Jr. Reclassification: Not Applicable to NAD+
As of March 2026, the anticipated RFK Jr. reclassification of approximately 14 peptides does not include NAD+ or its precursors. NAD+ is not a peptide and was not subject to the FDA enforcement actions that affected the peptide market. The oral supplement pathway for NMN and NR is fundamentally different from the compounded peptide pathway that has been the focus of FDA action.
Section 12
Community Q&A
These questions come directly from the NAD+ community: Reddit threads, biohacker forums, IV clinic review sections, and recovery community discussions. The answers reflect what the evidence actually supports.
Section 13
The VitalRx Model
This guide has told you that a 2025 meta-analysis found most clinical outcomes from NAD+ supplementation showed no significant difference from placebo despite blood NAD+ elevation. It has told you that IV NAD+ is challenged at the cellular level by leading researchers. It has told you that half of Amazon NAD+ products may contain negligible active ingredient. These are not disclaimers buried in small print. They are the clinical picture that any honest provider must address before asking for your business.
The reason VitalRx exists in this space is not that we have better marketing claims. It is that we have a structural answer to the documented failures: quality-verified products, physician oversight, baseline and follow-up measurement, and a protocol whose dose is determined by your actual biology rather than by marketing copy.
Quality-Verified Sourcing
Every product we recommend has a third-party Certificate of Analysis confirming active ingredient content. We have reviewed the testing documentation. You are not gambling on label claims in a market where 50%+ of top products fail independent quality testing.
Physician Oversight
A licensed physician reviews your baseline labs and health history before recommending NMN vs. NR, starting dose, and any contraindications. Dose adjustments are driven by your 8-week re-test results, not by marketing-determined defaults.
Measurement-Driven Protocol
Baseline blood NAD+ testing before you start. Follow-up at 8 weeks to confirm pharmacological activity. If your levels haven't moved, we adjust the protocol. You will know whether the intervention is working in your body.
Legal Access, Honest Claims
We operate within the DSHEA supplement pathway for oral protocols and the 503A compounding pathway for parenteral protocols where applicable. We do not claim regulatory certainty we don't have. We do not make anti-aging claims the evidence doesn't support. Legal, supervised, honest.
✦Ready to Start a Protocol That Measures What It Does
Your consultation includes the baseline blood NAD+ test, a physician review of your metabolic panel, a specific product recommendation with documentation, and a clear explanation of what to expect and what we will measure at 8 weeks. If you've spent money on this category before and didn't know if it worked, that changes with your first appointment.